The New York Times > Business > Importing Less Expensive Drugs Not Seen as Cure for U.S. Woes

Finally, a realistic review of the issues associated with drug pricing and why re-importation on a large scale is unlikely to be effective in the long run to reduce costs. I hope the advocates like Mayor Clavelle and Bernie Sanders take heed. More important will be a rational approach to this issue by lawmakers. There are mo easy answers to this dilemma. If drug R&D is reduced because less profitable revenue is available to the drug companies, will the public stand for that? And price controls seem unworkable. Perhaps we can find some way to get off our 'drug for everything' habit.